450,456 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Bought by Eagle Asset Management Inc.

Eagle Asset Management Inc. bought a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVAFree Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 450,456 shares of the biotechnology company’s stock, valued at approximately $3,662,000. Eagle Asset Management Inc. owned 0.18% of Iovance Biotherapeutics at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Annandale Capital LLC acquired a new stake in Iovance Biotherapeutics in the 3rd quarter worth $32,000. Clear Street Markets LLC acquired a new stake in Iovance Biotherapeutics in the 3rd quarter worth $35,000. Quadrant Capital Group LLC grew its position in Iovance Biotherapeutics by 1,227.8% in the 4th quarter. Quadrant Capital Group LLC now owns 5,059 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 4,678 shares during the last quarter. Pathstone Family Office LLC acquired a new stake in Iovance Biotherapeutics in the 3rd quarter worth $48,000. Finally, Nisa Investment Advisors LLC grew its position in Iovance Biotherapeutics by 284.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 7,541 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 5,577 shares during the last quarter. Institutional investors own 77.03% of the company’s stock.

Wall Street Analyst Weigh In

IOVA has been the topic of several research analyst reports. Piper Sandler raised their price target on shares of Iovance Biotherapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, March 14th. Wells Fargo & Company lifted their target price on shares of Iovance Biotherapeutics from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, March 1st. JMP Securities lifted their target price on shares of Iovance Biotherapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a research report on Tuesday, February 20th. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a research report on Friday, May 31st. Finally, Barclays lifted their target price on shares of Iovance Biotherapeutics from $18.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $24.64.

Check Out Our Latest Stock Report on Iovance Biotherapeutics

Iovance Biotherapeutics Price Performance

Shares of IOVA stock opened at $8.10 on Wednesday. Iovance Biotherapeutics, Inc. has a 12-month low of $3.21 and a 12-month high of $18.33. The firm has a 50-day moving average price of $11.92 and a 200 day moving average price of $10.56.

Iovance Biotherapeutics (NASDAQ:IOVAGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.03. Iovance Biotherapeutics had a negative net margin of 23,615.70% and a negative return on equity of 71.45%. The firm had revenue of $0.72 million during the quarter, compared to the consensus estimate of $1.99 million. During the same period last year, the firm posted ($0.50) EPS. The firm’s quarterly revenue was up 71400.0% on a year-over-year basis. On average, research analysts predict that Iovance Biotherapeutics, Inc. will post -1.35 EPS for the current year.

About Iovance Biotherapeutics

(Free Report)

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

Recommended Stories

Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics, Inc. (NASDAQ:IOVAFree Report).

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.